CT1190B is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is UCARsgen Biotech Limited (1). The most-studied condition is Large B-Cell Lymphoma (LBCL).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
NCT07470073 · ClinicalTrials.gov ↗ · ALL (Acute B-Lymphoblastic Leukemia)
|
Phase EARLY_PHASE1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | China |
|
A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma
NCT07823829 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma (LBCL)
|
Phase 1/2 | Not yet open | UCARsgen Biotech Limited | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| UCARsgen Biotech Limited | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name CT1190B (also registered as CT1190B cell) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
UCARsgen Biotech Limited (1) and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how CT1190B works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CT1190B works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CT1190B (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.